TY - JOUR
T1 - Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19
AU - HCA Lung Biological Network
AU - the Deutsche COVID-19 Omics Initiative (DeCOI)
AU - Bernardes, Joana P.
AU - Mishra, Neha
AU - Tran, Florian
AU - Bahmer, Thomas
AU - Best, Lena
AU - Blase, Johanna I.
AU - Bordoni, Dora
AU - Franzenburg, Jeanette
AU - Geisen, Ulf
AU - Josephs-Spaulding, Jonathan
AU - Köhler, Philipp
AU - Künstner, Axel
AU - Rosati, Elisa
AU - Aschenbrenner, Anna C.
AU - Bacher, Petra
AU - Baran, Nathan
AU - Boysen, Teide
AU - Brandt, Burkhard
AU - Bruse, Niklas
AU - Dörr, Jonathan
AU - Dräger, Andreas
AU - Elke, Gunnar
AU - Ellinghaus, David
AU - Fischer, Julia
AU - Forster, Michael
AU - Franke, Andre
AU - Franzenburg, Sören
AU - Frey, Norbert
AU - Friedrichs, Anette
AU - Fuß, Janina
AU - Glück, Andreas
AU - Hamm, Jacob
AU - Hinrichsen, Finn
AU - Hoeppner, Marc P.
AU - Imm, Simon
AU - Junker, Ralf
AU - Kaiser, Sina
AU - Kan, Ying H.
AU - Knoll, Rainer
AU - Lange, Christoph
AU - Laue, Georg
AU - Lier, Clemens
AU - Lindner, Matthias
AU - Marinos, Georgios
AU - Markewitz, Robert
AU - Nattermann, Jacob
AU - Rupp, Jan
AU - Wandinger, Klaus Peter
AU - Busch, Hauke
AU - Janssen, Stefan
N1 - Funding Information:
We thank K. Greve, M. Rohm, M. Hansen, S. Kock, D. Oelsner, S. Baumgarten, M. Reffelmann, M. Schlapkohl, N. Braun, T. Wesse, M. Basso, Y. Dolschanskaya, X. Yi, C. Lancken, and M. Vollstedt for perfect technical assistance. This work was supported by the German Research Foundation (DFG) CCGA Nr. 07495230 , a COVID-response grant of the state SH , ExC 2167 Precision Medicine in Chronic Inflammation ( RTF-VI ), the research group miTARGET and the CRC1182 C2 project to P.R.; the IMI2 Project 3TR to P.R. and S.S.; INST 37/1049-1 , INST 216/981-1 , INST 257/605-1 , INST 269/768-1 , INST 217/988-1 , INST 217/577-1 , and EXC2151/1 ( 390873048 ) to J.L.S.; SFB TR57 and SPP1937 to J.N.; Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany ( sparse2big ) to J.L.S.; EU projects SYSCID ( 733100 ) to P.R. and J.L.S.; the DZIF, Germany ( TTU 04.816 and 04.817 ) to J.N.; and the Hector Foundation ) ( M89 ) to J.N. A.D. acknowledges support by the DFG ( EXC 2124-390838134 Controlling Microbes to Fight Infections) and the German Center for Infection Research (DZIF grant N° 8020708703). C.K. acknowledges support by the DFG through EXC 2167 , RTF-VIII , and the CRC 1182 . This publication is part of the Human Cell Atlas ( www.humancellatlas.org/publications ). We are indebted to the patients, their families, and the hospital staff for support, without whom this study would not have been possible.
Publisher Copyright:
© 2020 Elsevier Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12/15
Y1 - 2020/12/15
N2 - Temporal resolution of cellular features associated with a severe COVID-19 disease trajectory is needed for understanding skewed immune responses and defining predictors of outcome. Here, we performed a longitudinal multi-omics study using a two-center cohort of 14 patients. We analyzed the bulk transcriptome, bulk DNA methylome, and single-cell transcriptome (>358,000 cells, including BCR profiles) of peripheral blood samples harvested from up to 5 time points. Validation was performed in two independent cohorts of COVID-19 patients. Severe COVID-19 was characterized by an increase of proliferating, metabolically hyperactive plasmablasts. Coinciding with critical illness, we also identified an expansion of interferon-activated circulating megakaryocytes and increased erythropoiesis with features of hypoxic signaling. Megakaryocyte- and erythroid-cell-derived co-expression modules were predictive of fatal disease outcome. The study demonstrates broad cellular effects of SARS-CoV-2 infection beyond adaptive immune cells and provides an entry point toward developing biomarkers and targeted treatments of patients with COVID-19.
AB - Temporal resolution of cellular features associated with a severe COVID-19 disease trajectory is needed for understanding skewed immune responses and defining predictors of outcome. Here, we performed a longitudinal multi-omics study using a two-center cohort of 14 patients. We analyzed the bulk transcriptome, bulk DNA methylome, and single-cell transcriptome (>358,000 cells, including BCR profiles) of peripheral blood samples harvested from up to 5 time points. Validation was performed in two independent cohorts of COVID-19 patients. Severe COVID-19 was characterized by an increase of proliferating, metabolically hyperactive plasmablasts. Coinciding with critical illness, we also identified an expansion of interferon-activated circulating megakaryocytes and increased erythropoiesis with features of hypoxic signaling. Megakaryocyte- and erythroid-cell-derived co-expression modules were predictive of fatal disease outcome. The study demonstrates broad cellular effects of SARS-CoV-2 infection beyond adaptive immune cells and provides an entry point toward developing biomarkers and targeted treatments of patients with COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85097363116&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2020.11.017
DO - 10.1016/j.immuni.2020.11.017
M3 - Journal articles
C2 - 33296687
AN - SCOPUS:85097363116
SN - 1074-7613
VL - 53
SP - 1296-1314.e9
JO - Immunity
JF - Immunity
IS - 6
ER -